A recent study reveals that patients who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who end traditional diet and exercise programs.
Published data in a prominent medical journal shows that while overweight people frequently drop a large proportion of their total mass while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying such medications must be aware of the risk of fast weight regain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of regain implies a return to starting mass within about a year and a half.
Analyzing Treatments
The research, which reviewed dozens of trials involving over 9,000 of patients, contrasted the effects of the injectable medications with older methods.
Researchers note that people who lose weight through diet and exercise generally see a more gradual creep back—around 100 grams monthly—post-intervention.
Understanding the Fast Regain
Doctors suggest the way of the drugs is key to understanding the heightened weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels several times higher than normal might result in the system to produce less of its own natural GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement means hunger is unsuppressed, making binge eating much more probable."
A Lifelong Issue?
The NHS suggest the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
A number of clinicians contend that, due to the significant potential of weight regain, the therapy should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who note that the results "highlight the persistent nature of obesity," similar to managing conditions like high blood pressure.
Patient Accounts
Users who have stopped the jabs explain a intense return of cravings.
"It was like a switch that goes on and I was suddenly starving," recalled a patient.
This challenge is compounded if patients have not adopted permanent lifestyle or habit changes during therapy.
Significant Use
Recent estimates suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is greater among females than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers stress that while these medications are potent tools for shedding pounds, they are not a standalone cure and long-term success relies on ongoing behavioural support.